[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"infants\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:infants":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,49,86,112,137,161],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100436511","neuraxial-labor-analgesia-and-offspring-neurodevelopment-100436511",false,"NCT04964206","Neuraxial Labor Analgesia and Offspring Neurodevelopment","Impact of Maternal Neuraxial Labor Analgesia on Offspring Neurodevelopment. A Multicenter, Prospective, Longitudinal Cohort Study","Inclusion Criteria:\n\n1. Primiparae between 18 and 35 years of age with term single cephalic pregnancy;\n2. Undergo regular prenatal examination in the study centers;\n3. Preparing to deliver vaginally.\n\nExclusion Criteria:\n\n1. History of psychiatric diseases (indicate those that are diagnosed before or during pregnancy by psychiatrists);\n2. History of diseases involving the hypothalamic-pituitary-adrenal axis;\n3. Presence of contraindications to epidural analgesia, which includes: (1) History of infectious disease of the central nervous system (poliomyelitis, cerebrospinal meningitis, encephalitis, etc.); (2) History of spinal or intra-spinal disease (trauma or surgery of spinal column, intra-spinal canal mass, etc.); (3) Systemic infection (sepsis); (4) Skin or soft tissue infection at the site of epidural puncture; (5) Coagulopathy.\n4. Presence of contraindications to vaginal delivery;\n5. Other reasons that are considered unsuitable for study participation.","FEMALE","18 Years","35 Years",{"count":20,"type":21},4645,"ESTIMATED","24 Months","OBSERVATIONAL","How perinatal factors affect the long-term development of children has always been an issue of much concern. This study is designed to explore the potential impact of maternal neuraxial labor analgesia exposure on offspring neurodevelopment.",[26,27,28,29,30],"Pregnant Women","Labor Pain","Analgesia, Epidural","Infants","Neurodevelopmental Disorders",[32,33,34,29,35],"Pregnant women","Labor pain","Neuraxial labour analgesia","Neurodevelopmental disorders","RECRUITING","2026-06-05",{"date":39,"type":40},"2026-06-09","ACTUAL",{"date":42,"type":40},"2022-10-14",{"date":44,"type":21},"2028-12",{"name":46,"class":47},"Dong-Xin Wang","OTHER",2,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":70,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":85},"100633879","probiotic-intervention-on-the-development-of-allergic-diseases-in-infants-exposed-to-antibiotics-early-in-life-100633879","NCT07532421","Probiotic Intervention on the Development of Allergic Diseases in Infants Exposed to Antibiotics Early in Life","A Study on the Impact of Probiotic Intervention on the Development of Allergic Diseases in Infants Exposed to Antibiotics Early in Life","Inclusion Criteria:\n\n* Gestational age from 37 weeks to less than 41 weeks;\n* Birth weight between the 10th and 90th percentiles for gestational age;\n* Breastfed (exclusively breastfed after achieving stable feeding volume, with willingness to maintain exclusive breastfeeding for at least 3 months);\n* Postnatal age within 35 days; Consent to participate in this study.\n\nExclusion Criteria:\n\n* Postnatal Apgar score \\\u003C7;\n* Presence of severe congenital malformations or inherited metabolic diseases;\n* Use of probiotics by the infant or the mother within 2 weeks before enrollment.",true,"ALL","1 Day","35 Days",{"count":61,"type":21},400,"INTERVENTIONAL",[64],"NA","Early antibiotic exposure is an important environmental factor that disrupts the establishment of the infant gut microbiota and leads to microbial dysbiosis. Accumulating epidemiological evidence indicates that exposure to antibiotics early in life (including both prenatal and postnatal periods) is significantly associated with an increased risk of allergic diseases in childhood. As live microorganisms, probiotics hold potential as a preventive strategy against allergies due to their ability to stabilize the intestinal barrier and regulate immune balance (e.g., promoting Th1\u002FTh2 balance, inducing regulatory T cells, and increasing sIgA secretion). However, current studies have mostly focused on general or high-risk infant populations. For the specific high-risk subgroup that has already been exposed to antibiotics early in life, high-quality randomized controlled trial evidence is still lacking regarding whether probiotic intervention can effectively reduce the incidence of allergies and whether it exerts its effects by reshaping the gut microbiota and metabolites disrupted by antibiotics.\n\nThis study focuses on breastfed infants who received antibiotics during the early postnatal period (within 30 days after birth) and aims to investigate the effect of a probiotic mixture containing Bifidobacterium longum subsp. infantis R0033, Lactobacillus helveticus R0052, and Bifidobacterium bifidum R0071 on the development of allergic diseases after antibiotic exposure.",[67,68,29,69],"Antibiotic","Allergic Diseases","Probiotic",[71,72,73,74],"probiotics","infants","early postnatal antibiotic exposure","allergic diseases","NOT_YET_RECRUITING","2026-05-06",{"date":78,"type":40},"2026-05-11",{"date":80,"type":21},"2026-04-17",{"date":82,"type":21},"2027-10-31",{"name":84,"class":47},"Peking University Third Hospital",1,{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":57,"minAge":94,"maxAge":95,"enrollmentInfo":96,"targetDuration":4,"studyType":62,"phases":98,"briefSummary":100,"conditions":101,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":4},"100609575","phase-2-caffeine-optimization-for-oxygen-saturation-index-in-elbw-infants-100609575","NCT07216365","Caffeine Optimization for Oxygen Saturation Index in ELBW Infants","Caffeine Optimization for Oxygen Saturation Index in ELBW Infants (COFIE Trial)","COFIE trail","Inclusion Criteria:\n\n* URMC Inborn Newborn infants born with gestational age of 22 weeks 0 days - 27 weeks 6 days or infants OR ≥ 28 weeks with a birthweight \\\u003C 1000 grams\n\nExclusion Criteria:\n\n* Hepatic failure, spontaneous intestinal perforation, necrotizing enterocolitis, Anticipated major congenital or genetic anomalies, infants not anticipated to survive beyond 72 hours, infants with mothers that are non-English speaking or \\\u003C18 years old at time of enrollment.","0 Days","27 Weeks",{"count":97,"type":21},40,[99],"PHASE2","The goal of this clinical trial is to determine whether a higher dose of caffeine citrate can improve breathing and reduce health complications in extremely premature infants, specifically those born before 28 weeks of pregnancy, known as ELGAN infants. These babies often struggle with breathing due to underdeveloped lungs, and caffeine is commonly used to help support their respiratory function. However, the most effective and safest dose has not yet been clearly established.\n\nThe study aims to answer two main questions: Does a higher maintenance dose of caffeine (10 mg\u002Fkg) lead to better oxygenation, as measured by the Oxygen Saturation Index (OSI), compared to the standard dose (5 mg\u002Fkg)? And does the higher dose reduce the risk of serious complications such as lung disease, brain injury, or death-without causing more side effects like fast heart rate, high blood pressure, or poor growth?\n\nTo answer these questions, researchers will compare two groups of infants: one receiving the high-dose caffeine treatment and the other receiving the standard dose. This comparison will help determine if the higher dose leads to better outcomes without increased risk.\n\nParticipants will begin caffeine treatment once they have regained their birth weight and are at least seven days old. They will be randomly assigned to receive either the high or standard caffeine dose and will be followed until caffeine is stopped or they are discharged from the hospital. During this time, researchers will monitor each infant's oxygenation levels, need for breathing support, signs of common complications, growth and feeding progress, and any side effects. Before discharge, each infant's motor development will also be assessed using a tool called the Test of Infant Motor Performance (TIMP).\n\nThis study could help define the most effective caffeine dosing strategy for supporting extremely premature infants and improving their short-term health outcomes.",[102,29],"Neonatal Apnea","2026-04-28",{"date":105,"type":40},"2026-05-04",{"date":107,"type":21},"2026-06-01",{"date":109,"type":21},"2028-09-01",{"name":111,"class":47},"University of Rochester",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":56,"sex":16,"minAge":120,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":62,"phases":123,"briefSummary":124,"conditions":125,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":4},"100525913","learning-early-infant-feeding-cues-100525913","NCT06127914","Learning Early Infant Feeding Cues","A Multiphase Project to Improve Use of Responsive Feeding Among Vulnerable Mother-Infant Dyads","LEIFc","Maternal Inclusion Criteria\n\n* Pregnant mother in the 3rd trimester (28 weeks or beyond)\n* Enrolled in a government-funded maternal-child home visiting program\n* Maternal age 18 years or older\n* English or Spanish speaking\n* Anticipated to have custody of infant after birth\n* Healthy pregnancy, no complications that are anticipated to result in a preterm birth or extended hospital stay for mother or infant\n\nMaternal Exclusion Criteria\n\n* Gave birth to multiple fetuses\n* Age less than 18 years\n* Not fluent in English or Spanish\n* Expected to not have custody of the infant after birth\n\nInfant inclusion criteria\n\n* Born as a singleton (not a twin, triplet, etc.) to a mother enrolled in a maternal-child home visiting program\n* Born full term (37 weeks or beyond)\n\nInfant exclusion criteria\n\n* Congenital anomaly that may interfere with infant feeding or growth after birth (i.e., Down Syndrome, cleft lip\u002Fpalate)\n* Born preterm (born prior to 37 weeks)\n* NICU stay beyond 48 hours\n* Infant diagnosis of failure to thrive\n* Supplemental oxygen\n* Enteral feeding device used for feedings","2 Weeks",{"count":122,"type":21},39,[64],"The goal of this clinical trial is to learn more about responsive infant feeding (recognizing baby's signs of hunger and fullness) in mothers and infant enrolled in government-funded maternal-child home visiting programs. The main questions it aims to answer are:\n\n* What are the contributors and barriers to use of responsive infant feeding?\n* How can we refine an intervention focused on responsive infant feeding (the Learning Early Infant Feeding Cues intervention) so that mothers will like it and learn skills to help their baby be healthy.\n* Will the refined intervention improve use of responsive feeding and be feasible and acceptable to mothers and home visiting programs?\n\nParticipants will be asked to:\n\n* Participate in focus groups to talk about their experiences feeding their baby.\n* Participate in a study to learn about responsive feeding and how to use it with their baby. This study will start when mothers are in their final month of pregnancy and finish when their baby is 6 months old. Participation will include:\n\n  * Having someone come to the family home during a time when the baby is eating (either from the breast or the bottle). The mother will receive information on the baby's signs from an experienced coach.\n  * Agreeing to be video recording during the session when the baby is eating.\n  * Completing surveys online.",[126,29,127],"Responsive Feeding","Weight Gain Trajectory","2026-04-22",{"date":130,"type":40},"2026-04-27",{"date":132,"type":21},"2027-07-01",{"date":134,"type":21},"2029-06-30",{"name":136,"class":47},"Florida State University",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":57,"minAge":144,"maxAge":145,"enrollmentInfo":146,"targetDuration":4,"studyType":62,"phases":148,"briefSummary":149,"conditions":150,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":159,"locationsCount":85},"100582375","open-surgical-modified-seldingers-and-us-techniques-for-jugular-central-line-insertion-in-infants-100582375","NCT06862492","Open Surgical, Modified Seldinger's and US Techniques for Jugular Central Line Insertion in Infants","Comparing Open Surgical, Modified Seldinger's and Ultrasound Guided Techniques for Jugular Central Line Insertion in Infants","Inclusion Criteria:\n\n\\- 1-patients needed Central venous catheterization insertion in the internal jugular vein for medical or surgical causes.\n\n2- patients with age ranging from birth till two years\n\nExclusion Criteria:\n\n* 1- femoral or subclavian Central venous catheterization insertion. 2- patients with thrombosed internal jugular vein . 3- patients with previous Central venous catheterization insertion. 4- those with malignant conditions","1 Hour","18 Months",{"count":147,"type":21},35,[64],"The aim of this study was to compare the three approaches: open technique, modified Seldinger's technique and closed ultrasound-guided Central venous catheterization insertion for central line insertion in infancy as regards safety, success of cannulation, technique time, and preservation of the patency of the internal jugular vein.",[29,151,152],"Intensive Care Unit","Central Venous Catheterization","2025-03-06",{"date":155,"type":40},"2025-03-11",{"date":157,"type":21},"2025-08-21",{"date":157,"type":21},{"name":160,"class":47},"Tanta University",{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":56,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":168,"targetDuration":4,"studyType":62,"phases":170,"briefSummary":171,"conditions":172,"keywords":174,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":186,"locationsCount":85},"100540610","effect-of-consumption-of-a-milk-product-designed-for-lactating-women-on-human-milk-composition-100540610","NCT06319079","Effect of Consumption of a Milk Product Designed for Lactating Women on Human Milk Composition","Effect of Consumption of a Milk Product Designed for Lactating Women on Human Milk Composition and Nutritional Status of Iron and DHA in Infant Red Blood Cells.. Study in a Vulnerable Population.","Inclusion Criteria:\n\n* Women who attend their child's first check-up within the first month of life, who breastfeed their children, and who consume milk regularly.\n\nExclusion Criteria:\n\n* Women who have had multiple pregnancies, who receive vitamin or mineral supplements that interfere with the results of the study, and\u002For women with malabsorption diseases.",{"count":169,"type":21},120,[64],"Vulnerable populations, who have deficient diets, may produce human milk (HML) that is not adequate in all nutrients and this will have consequences on the growth and development of the child. In 2021 at IDIP, a specific milk product for pregnant and lactating women Super Mil Mamá ( SMM, whole milk powder fortified with multiple vitamins, minerals and DHA ) has been designed and developed as part of a key strategy to incorporate in public policies for the first 1000 days of life. However, the potential benefits of this product have not yet been evaluated at the population level.\n\nThe main objective is to evaluate the effect of the consumption of a milk product (SMM) designed for lactating women on the composition of human milk and the nutritional status of iron and DHA in infant red blood cells in a vulnerable population through a randomized, triple-blind, controlled clinical trial.\n\nSpecific objectives To compare the concentrations of DHA, Vitamins A, E, and D, Iron, Iodine, Zinc and Calcium in human milk before and after dietary supplementation with SMM.\n\nTo compare the concentrations of DHA, Vitamins A, E, D and Zinc in blood and the nutritional status of maternal iron before and after dietary supplementation with SMM.\n\nTo analyze the relationship between micronutrients measured in maternal blood and human milk after dietary supplementation with SMM.\n\nTo compare the concentrations of micronutrients measured in blood and human milk in women who received SMM and those who received commercial milk (CM) at the end of supplementation.\n\nTo compare the iron nutritional status and DHA content in red blood cells of infants of mothers who consumed SMM or LC.\n\nTo evaluate the relationship between the concentration of micronutrients in human milk and infant growth during the first six months of life.",[173,29],"Lactating Mothers",[175,176,177,178,179],"human milk","vulnerable population","micronutrients","esencial fatty acids","nutritional supplements","2024-09-25",{"date":182,"type":40},"2024-09-27",{"date":184,"type":40},"2024-06-01",{"date":132,"type":21},{"name":187,"class":47},"Instituto de Desarrollo e Investigaciones Pediátricas Prof. Dr. Fernando E. Viteri"]